Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head

LAUR Repository

Show simple item record

dc.contributor.author Varadhachary, Gauri
dc.contributor.author Wolff, Robert
dc.contributor.author Crane, Christopher
dc.contributor.author Sun, Charlotte
dc.contributor.author Lee, Jeffrey
dc.contributor.author Pisters, Peter
dc.contributor.author Vauthey, Jean-Nicolas
dc.contributor.author Abdalla, Eddie
dc.contributor.author Wang, Huamin
dc.contributor.author Staerkel, Gregg
dc.contributor.author Ross, William
dc.contributor.author Tamm, Eric
dc.contributor.author Bhosale, Priya
dc.contributor.author Krishnan, Sunil
dc.contributor.author Das, Prajnan
dc.contributor.author Ho, Linus
dc.contributor.author Xiong, Henry
dc.contributor.author Abbruzzese, James
dc.contributor.author Evans, Douglas
dc.date.accessioned 2015-11-17T09:14:38Z
dc.date.available 2015-11-17T09:14:38Z
dc.date.copyright 2007
dc.date.issued 2015-11-17
dc.identifier.issn 0022-4790 en_US
dc.identifier.uri http://hdl.handle.net/10725/2594
dc.description.abstract Purpose We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma. Patients and Methods Chemotherapy consisted of gemcitabine (750 mg/m2) and cisplatin (30 mg/m2) given every 2 weeks for four doses. Chemoradiation consisted of four weekly infusions of gemcitabine (400 mg/m2) combined with radiation therapy (30 Gy in 10 fractions administered over 2 weeks) delivered 5 days per week. Patients underwent restaging 4 to 6 weeks after completion of chemoradiation and, in the absence of disease progression, were taken to surgery. Results The study enrolled 90 patients; 79 patients (88%) completed chemo-chemoradiation. Sixty-two (78%) of 79 patients were taken to surgery and 52 (66%) of 79 underwent PD. The median overall survival of all 90 patients was 17.4 months. Median survival for the 79 patients who completed chemo-chemoradiation was 18.7 months, with a median survival of 31 months for the 52 patients who underwent PD and 10.5 months for the 27 patients who did not undergo surgical resection of their primary tumor (P < .001). Conclusion Preoperative Gem-Cis-XRT did not improve survival beyond that achieved with preoperative gemcitabine-based chemoradiation (Gem-XRT) alone. The longer preoperative interval required more durable biliary decompression (metal stents) but was not associated with local tumor progression. The gemcitabine-based chemoradiation platform is a reasonable foundation on which to build future phase II multimodality trials for stage I/II pancreatic cancer incorporating emerging systemic therapies. en_US
dc.language.iso en en_US
dc.title Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Journal of Clinical Oncology en_US
dc.journal.volume 26 en_US
dc.journal.issue 21 en_US
dc.article.pages 3487-3495 en_US
dc.identifier.doi http://dx.doi.org/10.1200/JCO.2007.15.8642 en_US
dc.identifier.ctation Varadhachary, G. R., Wolff, R. A., Crane, C. H., Sun, C. C., Lee, J. E., Pisters, P. W., ... & Evans, D. B. (2008). Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology, 26(21), 3487-3495. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://jco.ascopubs.org/content/26/21/3487.short

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account